14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis AI Analysis of ABIO
Powered by GPT-4o
Stock Analysis
Risk Assessment
Trading Strategy
PDF

ARCA biopharma stock price down 0% on Thursday
(Updated on Oct 03, 2024)

Hold candidate since Sep 04, 2024

No changes to the price of ARCA biopharma stock on the last trading day (Thursday, 3rd Oct 2024). During the last trading day the stock fluctuated 0% from a day low at $2.40 to a day high of $2.40. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.10% during the next 3 months and, with a 90% probability hold a price between $1.05 and $2.77 at the end of this 3-month period.

ABIO Signals & Forecast

There are mixed signals in the stock today. The ARCA biopharma stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.40 and $2.75. A break-up above any of these levels will issue buy signals. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued. A buy signal was issued from a pivot bottom point on Friday, August 30, 2024, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for ARCA biopharma stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 0%

Our recommended stop-loss: $2.26 (-6.00%) (This stock has low daily movements and this gives low risk. There is a buy signal from a pivot bottom found 23 days ago.)

Trading Expectations (ABIO) For The Upcoming Trading Day Of Friday 4th

For the upcoming trading day on Friday, 4th we expect ARCA biopharma to open at $2.40, and during the day (based on 14 day Average True Range), to move between $2.33 and $2.47, which gives a possible trading interval of +/-$0.0731 (+/-3.04%) up or down from last closing price. If ARCA biopharma takes out the full calculated possible swing range there will be an estimated 6.09% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $2.50, some $0.100 (4.17%) from the current price of $2.40, our system finds the risk reward not very attractive.

Is ARCA biopharma stock A Buy?

ARCA biopharma holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: 0.000 Hold/Accumulate Unchanged

Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

Predicted Fair Opening Price

Predicted fair opening price on October 4, 2024 - $2.40 ( 0%). The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ABIO

Fibonacci Support & Resistance Levels

Level Price
R3 2.40 -
R2 2.40 -
R1 2.40 -
Price 2.40
S1 2.40 -
S2 2.40 -
S3 2.40 -

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.90 20.83%
R2 2.74 14.17%
R1 2.50 4.17%
Price 2.40
S1 0 -
S2 0 -
S3 0 -

ABIO Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Aug 29, 2024 Aug 29, 2024 Aug 29, 2024 $1.59 5.30%
2 Aug 26, 2024 Aug 26, 2024 Aug 28, 2024 $1.59 3.80%

FAQ

What is the symbol for ARCA biopharma Stock and on which exchange is it traded?
The symbol for ARCA biopharma is ABIO and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell ARCA biopharma Stock?
ARCA biopharma holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy ARCA biopharma Stock?
ARCA biopharma Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy ARCA biopharma Stock.

What's the current price of ARCA biopharma Stock?
As of the end of day on the Oct 03, 2024, the price of an ARCA biopharma (ABIO) share was $2.40.

What is the 52-week high and low for ARCA biopharma Stock?
The 52-week high for ARCA biopharma Stock is $4.49 and the 52-week low is $1.56.

What is the market capitalization of ARCA biopharma Stock?
As of the Oct 03, 2024, the market capitalization of ARCA biopharma is 34.817M.

When is the next earnings date for ARCA biopharma?
The upcoming earnings date for ARCA biopharma is Oct 16, 2024.
Click to get the best stock tips daily for free!
ABOUT ARCA BIOPHARMA
ARCA biopharma
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase...
GOLDEN STAR
Ticker Change Signal Date
WM
$207.93
0.558% Oct 01
VET
$9.77
7.06% Sep 30
FSK
$19.73
1.57% Sep 30
XOM
$115.82
5.84% Sep 27
HES
$133.61
5.43% Sep 27

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE